Screener
Neurocrine Biosciences NBIX Business Segments — Acquired in-process research and development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Operating expenses: | ||
| Cost of revenues | 13.8 | 9.2 |
| Research and development | 296.2 | 263.2 |
| Acquired in-process research and development | 21.2 | 0.1 |
| Selling, general, and administrative | 318.5 | 276.5 |
| Gain on sale of business, net of transaction costs | (28.6) | — |
| Total operating expenses | 621.1 | 549.0 |
| Operating income | 193.4 | 23.6 |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's business segments — acquired in-process research and development?
- Neurocrine Biosciences (NBIX) reported business segments — acquired in-process research and development of $21.2M in Q1 2026.
- How has Neurocrine Biosciences's business segments — acquired in-process research and development changed year-over-year?
- Neurocrine Biosciences's business segments — acquired in-process research and development increased by 21100.0% year-over-year, from $100K to $21.2M.
- What does business segments — acquired in-process research and development mean?
- Reflects the costs associated with acquiring intellectual property or clinical-stage assets from third parties. This represents inorganic growth strategies to bolster the pipeline through external innovation.
Ask your AI about Neurocrine Biosciences's business segments — acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude